In a report released yesterday, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Zevra Therapeutics (ZVRA – Research Report), with a price target of $25.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sumant Kulkarni has given his Buy rating due to a combination of factors that highlight Zevra Therapeutics’ promising outlook. The company’s recent performance, particularly with the launch of Miplyffa for Niemann-Pick Type C, has been encouraging, with sales surpassing expectations and prescription numbers increasing. This positive trend is a key driver for the stock in the near to mid-term. Additionally, Zevra’s strategic focus on rare diseases is seen as undervalued by the market, providing a potential for significant upside.
Moreover, the company’s financial position is strong, with a solid cash runway extending into 2029, excluding the proceeds from the sale of a pediatric priority review voucher. This sale has also contributed to an increase in the price target from $23 to $25. The analyst maintains conservative estimates for other products like Olpruva, but the overall strategy and financial health of the company support the Buy rating, indicating confidence in its future growth potential.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.